Jonathan Herskovitz
Jonathan Herskovitz
Verified email at
Cited by
Cited by
Blockade of chronic type I interferon signaling to control persistent LCMV infection
EB Wilson, DH Yamada, H Elsaesser, J Herskovitz, J Deng, G Cheng, ...
Science 340 (6129), 202-207, 2013
The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections
J Machhi, J Herskovitz, AM Senan, D Dutta, B Nath, MD Oleynikov, ...
Journal of neuroimmune pharmacology 15, 359-386, 2020
Diagnostics for SARS-CoV-2 infections
BD Kevadiya, J Machhi, J Herskovitz, MD Oleynikov, WR Blomberg, ...
Nature materials 20 (5), 593-605, 2021
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
MK Joubert, M Deshpande, J Yang, H Reynolds, C Bryson, M Fogg, ...
PloS one 11 (8), e0159328, 2016
Amyloid precursor protein and amyloid precursor-like protein 2 in cancer
P Pandey, B Sliker, HL Peters, A Tuli, J Herskovitz, K Smits, A Purohit, ...
Oncotarget 7 (15), 19430, 2016
Nanocarrier vaccines for SARS-CoV-2
J Machhi, F Shahjin, S Das, M Patel, MM Abdelmoaty, JD Cohen, ...
Advanced Drug Delivery Reviews 171, 215-239, 2021
Type I and type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence
CR Cunningham, A Champhekar, MV Tullius, BJ Dillon, A Zhen, ...
PloS pathogens 12 (1), e1005356, 2016
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
J Machhi, BD Kevadiya, IK Muhammad, J Herskovitz, KE Olson, ...
Molecular neurodegeneration 15, 1-26, 2020
CD4+ effector T cells accelerate Alzheimer’s disease in mice
J Machhi, P Yeapuri, Y Lu, E Foster, R Chikhale, J Herskovitz, ...
Journal of neuroinflammation 18, 1-23, 2021
HIV and the macrophage: from cell reservoirs to drug delivery to viral eradication
J Herskovitz, HE Gendelman
Journal of Neuroimmune Pharmacology 14, 52-67, 2019
A role for extracellular vesicles in SARS-CoV-2 therapeutics and prevention
J Machhi, F Shahjin, S Das, M Patel, MM Abdelmoaty, JD Cohen, ...
Journal of Neuroimmune Pharmacology 16, 270-288, 2021
CRISPR-Cas9 mediated exonic disruption for HIV-1 elimination
J Herskovitz, M Hasan, M Patel, WR Blomberg, JD Cohen, J Machhi, ...
EBioMedicine 73, 2021
Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues
BD Kevadiya, B Ottemann, IZ Mukadam, L Castellanos, K Sikora, ...
Theranostics 10 (2), 630, 2020
Creation of a long-acting rilpivirine prodrug nanoformulation
JR Hilaire, AN Bade, B Sillman, N Gautam, J Herskovitz, BLD Shetty, ...
Journal of Controlled Release 311, 201-211, 2019
A long acting nanoformulated lamivudine ProTide
N Smith, AN Bade, D Soni, N Gautam, Y Alnouti, J Herskovitz, IM Ibrahim, ...
Biomaterials 223, 119476, 2019
Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking
IZ Mukadam, J Machhi, J Herskovitz, M Hasan, MD Oleynikov, ...
Biomaterials 231, 119669, 2020
Synthesis of a long acting nanoformulated emtricitabine ProTide
D Soni, AN Bade, N Gautam, J Herskovitz, IM Ibrahim, N Smith, ...
Biomaterials 222, 119441, 2019
The immunopathobiology of SARS-CoV-2 infection
M Patel, F Shahjin, JD Cohen, M Hasan, J Machhi, H Chugh, S Singh, ...
FEMS Microbiology Reviews 45 (6), fuab035, 2021
Pharmacotherapeutics of SARS-CoV-2 infections
BD Kevadiya, J Machhi, J Herskovitz, MD Oleynikov, WR Blomberg, ...
Journal of Neuroimmune Pharmacology 16, 12-37, 2021
Immune suppression during preclinical drug development mitigates immunogenicity-mediated impact on therapeutic exposure
J Herskovitz, J Ryman, T Thway, S Lee, L Zhou, N Chirmule, B Meibohm, ...
The AAPS journal 19, 447-455, 2017
The system can't perform the operation now. Try again later.
Articles 1–20